S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:PACB

Pacific Biosciences of California (PACB) Stock Forecast, Price & News

$7.84
-0.21 (-2.61%)
(As of 10/3/2023 ET)
Compare
Today's Range
$7.80
▼
$8.15
50-Day Range
$8.05
▼
$13.50
52-Week Range
$5.50
▼
$14.55
Volume
4.93 million shs
Average Volume
3.91 million shs
Market Capitalization
$1.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.10
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Pacific Biosciences of California MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
67.1% Upside
$13.10 Price Target
Short Interest
Bearish
13.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Pacific Biosciences of California in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$1.25 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.18) to ($1.01) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

837th out of 976 stocks

Analytical Instruments Industry

25th out of 29 stocks

See Top Rated MarketRank™ Stocks Here

PACB stock logo

About Pacific Biosciences of California (NASDAQ:PACB) Stock

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PACB Price History

PACB Stock News Headlines

October 1, 2023 | americanbankingnews.com
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Susan G. Kim Sells 19,257 Shares
October 1, 2023 | americanbankingnews.com
Pacific Biosciences of California (NASDAQ:PACB) PT Lowered to $9.00
October 3, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
September 30, 2023 | americanbankingnews.com
Pacific Biosciences of California (NASDAQ:PACB) Coverage Initiated at Sanford C. Bernstein
September 28, 2023 | msn.com
Bernstein Initiates Coverage of Pacific Biosciences of California (PACB) with Outperform Recommendation
September 27, 2023 | americanbankingnews.com
Pacific Biosciences of California (NASDAQ:PACB) Given "Neutral" Rating at Cantor Fitzgerald
September 26, 2023 | markets.businessinsider.com
5 Analysts Have This to Say About Pacific Biosciences
September 18, 2023 | finance.yahoo.com
Is Pacific Biosciences of California (PACB) Too Good to Be True? A Comprehensive Analysis of a ...
October 3, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
September 14, 2023 | finance.yahoo.com
Unraveling the Challenges Ahead for Pacific Biosciences of California Inc (PACB)
September 14, 2023 | finance.yahoo.com
Unveiling Pacific Biosciences of California (PACB)'s Value: Is It Really Priced Right? A ...
September 14, 2023 | finance.yahoo.com
Strength Seen in Pacific Biosciences (PACB): Can Its 8.9% Jump Turn into More Strength?
September 13, 2023 | finance.yahoo.com
Pacific Biosciences of California Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
September 12, 2023 | finance.yahoo.com
PacBio Announces PacBio Capital
September 10, 2023 | msn.com
Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Market
September 8, 2023 | finance.yahoo.com
Cathie Wood's Buying These 3 Stocks Hand Over Fist
September 7, 2023 | finance.yahoo.com
PacBio Announces Collaboration with Leading Library Preparation Automation Partners
August 23, 2023 | msn.com
Cantor Fitzgerald Reiterates Pacific Biosciences of California (PACB) Neutral Recommendation
August 8, 2023 | msn.com
Cathie Wood plows $6 million into Pacific Biosciences
August 7, 2023 | markets.businessinsider.com
Goldman Sachs Keeps Their Buy Rating on Pacific Biosciences (PACB)
August 7, 2023 | finance.yahoo.com
Time to Nail Down Profits in One of My Top Picks
August 4, 2023 | finance.yahoo.com
PacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)
August 4, 2023 | finance.yahoo.com
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S Is On The Mark
August 3, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for Pacific Biosciences
August 3, 2023 | finance.yahoo.com
PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View
August 3, 2023 | markets.businessinsider.com
Pacific Biosciences of California, Inc. Q2 Loss Decreases, beats estimates
August 3, 2023 | markets.businessinsider.com
Barclays Keeps Their Hold Rating on Pacific Biosciences (PACB)
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Company Calendar

Last Earnings
8/02/2023
Today
10/03/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
CIK
1299130
Web
www.pacb.com
Phone
(650) 521-8000
Fax
302-636-5454
Employees
769
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$13.10
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+67.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-314,250,000.00
Net Margins
-218.43%
Pretax Margin
-218.43%
Return on Equity
-46.47%
Return on Assets
-16.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.45
Quick Ratio
3.20

Sales & Book Value

Annual Sales
$128.30 million
Price / Sales
15.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.49 per share
Price / Book
3.15

Miscellaneous

Outstanding Shares
250,560,000
Free Float
247,050,000
Market Cap
$1.96 billion
Optionable
Optionable
Beta
1.72

Social Links

12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Christian O. Henry M.B.A. (Age 55)
    Pres, CEO & Director
    Comp: $1.1M
  • Ms. Susan G. KimMs. Susan G. Kim (Age 47)
    Chief Financial Officer
    Comp: $564.87k
  • Mr. Mark Van Oene (Age 50)
    Chief Operating Officer
    Comp: $772.11k
  • Mr. Jeff Eidel (Age 46)
    Chief Commercial Officer
    Comp: $435.62k
  • Dr. Stephen Turner (Age 55)
    Co-Founder & CTO
  • Ms. Michele Farmer CPA (Age 43)
    VP & Chief Accounting Officer
  • Dr. Jonas Korlach Ph.D.
    Chief Scientific Officer
  • Trevin Rard
    Head of Investor Relations
  • Dr. Brett Atkins J.D.
    Ph.D., Gen. Counsel & Corp. Sec.
  • Ms. Natalie Welch
    Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PACB Stock - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PACB shares.
View PACB analyst ratings or view top-rated stocks.

What is Pacific Biosciences of California's stock price forecast for 2023?

9 brokerages have issued 12-month price objectives for Pacific Biosciences of California's stock. Their PACB share price forecasts range from $9.00 to $17.00. On average, they anticipate the company's stock price to reach $13.10 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price.
View analysts price targets for PACB or view top-rated stocks among Wall Street analysts.

How have PACB shares performed in 2023?

Pacific Biosciences of California's stock was trading at $8.18 on January 1st, 2023. Since then, PACB stock has decreased by 4.2% and is now trading at $7.84.
View the best growth stocks for 2023 here.

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our PACB earnings forecast.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06. The biotechnology company earned $47.57 million during the quarter, compared to the consensus estimate of $40.12 million. Pacific Biosciences of California had a negative net margin of 218.43% and a negative trailing twelve-month return on equity of 46.47%. Pacific Biosciences of California's quarterly revenue was up 34.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.34) EPS.

What ETFs hold Pacific Biosciences of California's stock?

ETFs with the largest weight of Pacific Biosciences of California (NASDAQ:PACB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), AXS Green Alpha ETF (NXTE), ARK Innovation ETF (ARKK), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and BNY Mellon Innovators ETF (BKIV).

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $7.84.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $1.96 billion and generates $128.30 million in revenue each year. The biotechnology company earns $-314,250,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

The company employs 769 workers across the globe.

Does Pacific Biosciences of California have any subsidiaries?
The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More
How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.

This page (NASDAQ:PACB) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -